Cancer of the Paranasal Sinuses.
Chemotherapy
Clinical outcomes
Epidemiology
Radiation
Sinonasal cancer
Surgery
Treatment
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
pubmed:
7
7
2021
medline:
19
3
2022
entrez:
6
7
2021
Statut:
ppublish
Résumé
Sinonasal malignancies rare and pathologically diverse and make up <1% of all malignancies. Due to their anatomical location, they can cause significant morbidity with involvement of surrounding critical structures. They often present at a late stage with insidious onset of symptoms. Treatment of sinonasal malignancies is challenging and they often require a multimodality approach with surgery, radiation, and chemotherapy. Outcomes are poor with 5-year overall survival around 32%, but this varies greatly depending on histologic subtype. There is an urgent need for more randomized controlled trials to better define the appropriate therapeutic regimens and to improve clinical outcomes.
Identifiants
pubmed: 34226078
pii: S0889-8588(21)00062-9
doi: 10.1016/j.hoc.2021.05.006
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
949-962Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.